---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001518"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:22:37.676411+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HBIO Q4 revenue $28.4M (-14% YoY), GAAP net loss $1.7M; guides low-single-digit growth in FY23

## Summary
- Revenues $28.4M, down 14% YoY; negative currency impact of $1.0M.
- GAAP operating loss $0.5M vs income $1.7M; GAAP diluted EPS -$0.04 vs $0.02.
- Adjusted EPS $0.04 vs $0.08; adjusted EBITDA $3.7M vs $5.7M.
- FY23 guidance: low-to-mid single-digit revenue growth, improving gross margin, adjusted EBITDA expansion.
- Plans to reduce leverage ratio to ~2x by year end with improved margins and working capital.

## SEC filing metadata
- accession: 0001171843-23-001518
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184323001518/0001171843-23-001518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184323001518/f8k_030923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001518
- JSON: https://secwatch.observer/filing/0001171843-23-001518.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001518.txt

## Key facts
- Earnings Releases
  HARVARD BIOSCIENCE INC reported the fourth quarter and year ended December 31, 2022 results: revenue $28.4 million, net income $(1.7) M, EPS $(0.04).
  - Period: the fourth quarter and year ended December 31, 2022
  - Revenue: $28.4 million
  - Net income: $(1.7) M
  - EPS: $(0.04)
  - Result: reported results
  source text: Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative currency impact of $1.0 million. During the quarter ended December 31, 2022, our cellular and molecular
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184323001518/0001171843-23-001518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.